Alloy Therapeutics, Inc.

🌱 Alloy is growing at Granta Park as we continue our mission to empower the global scientific community in the pursuit of better medicines. Looking forward to this next chapter for the Alloy UK Team. 👏 Leigh Doyle, Davide Schiavone, Meera Sivasubramaniam, Mathilde Cathébras, Yasmin Goodfellow, Abbie Jayyaratnam #AlloyTherapeutics #LifeSciences #Biotech #CambridgeUK #makemedicinetogether #maythebestdrugwin

Thank you to everyone who joined us for Alloy’s 2025 R&D Day on March 25th! 🎉🧬 We had a full house—nearly 200 people from across the biotech community came together for a day of science, innovation, and collaboration. A big shoutout to our presenters from across Alloy and our partners: 🐁 Matthew Holsti, Pfizer shared how we’re innovating together through the Common Light Chain (CLC) mice—an incredible example of ecosystem collaboration in action   🌎 Mike Schmidt, Alloy Therapeutics, Inc. presented real-world data from 82VS portfolio companies developing bispecifics, offering insight into how Alloy’s platforms are powering next-gen therapeutics 🧬 Carlos Loya, 82VS introduced exciting work on antibody-oligonucleotide conjugates (AOCs) and their future in drug delivery 💭 Heather Schwoebel, Alloy Therapeutics, Inc. led a forward-looking panel discussion alongside Morris Rosenberg, MRBC, Bryan Glaser, Invenra, and Nicolas Camper, Abzena, diving into the future of ADCs, AOCs, and novel biologics Events like this are a cornerstone of our mission: building an open, vibrant community to accelerate the next generation of medicines 🚀 Don’t miss out on our upcoming events! Subscribe here 👉 https://lnkd.in/e74BbGgW #makemedicinetogether #maythebestdrugwin #AlloyRnDDay #Innovation #AlloyTx #DrugDiscovery #LifeSciences #Networking #Bispecifics #ADC #AOC #BiotechCommunity

So proud to work with Errik and the great team surrounding him at Alloy because the mission is helping patients. Errik often posits a question to the company..."What if drug discovery was completely free?" Think about it... Best tools, best science, best people, best company!

We’re thrilled to announce that our Errik Anderson, CEO and Founder of Alloy Therapeutics, Inc. and General Partner 82VS will be speaking on the Innovation Panel at The 7th Annual Emerging Frontiers in Oncology. In this high-energy discussion, industry leaders will tackle the pressing question: Should stakeholders wait and see or take bold, strategic bets as we look ahead to 2025? This dynamic panel will feature thought leaders who are shaping the future of oncology: Errik Anderson - CEO and Founder, Alloy Therapeutics, Inc., General Partner, 82VS Alexis Borisy - Operating Chairman, Curie.Bio Irina Margine, Ph.D., PhD - Biotech Sector Lead, Wellington Management Jean-Francois Formela, MD - Partner, Atlas Ventures Keith Flaherty, MD - Professor, Mass General Hospital; Co-founder Loxo Oncology, Scorpion Therapeutics Joseph Pearlberg, MD PhD, MD, PhD - VP of Scientific Affairs, Deerfield Management Moderator: Prashant Girinath, PhD - Shareholder, Greenberg Traurig, LLP Join us May 22nd, 1–8 PM | MassBio | Catalyst Reception Learn more and register here : https://lnkd.in/gCfAcBX

We’re excited to partner with Multiomic Health to develop first-in-class, renal tissue-targeting therapies. By combining MultiOmic’s AI-enabled discovery platform with Alloy’s bispecific antibody and genetic medicine technologies, we aim to deliver safer, more effective precision treatments. This collaboration builds on our ecosystems growing momentum and shared commitment to advancing innovative medicines for patients. #makemedicinetogether #maythebestdrugwin

We are excited to see everyone at the #TCRSummit this week in Boston! Come learn from our expert, Dongxing Zha on April 2nd, as he will be presenting and sharing how to target pHLA for solid tumors using #KeywayTCR workflow for #TCRmimic discovery. While you are at the conference, swing by our booth to chat with the team, Scott McMenemy and Eugene Mironets, and explore more ways to accelerate your antibody-based therapeutic pipeline. #antibodydiscover #makemedicinetogether #maythebestdrugwin

Alloy Therapeutics, Inc. CEO and Founder Errik Anderson had the pleasure of speaking with BiotechTV’s Brad Loncar for an interview at our R&D Day earlier this week. The two discussed the latest developments regarding several of Alloy’s core modalities, including bispecifics, TCR mimics, and genetic medicines – they also touched on their newly discovered cross-town high school sports rivalry. https://lnkd.in/g6p8HE32 #makemedicinetogether #AlloyRnDDay #maythebestdrugwin

In this weeks Biotech Leader Spotlight we are recognizing Ugur Eskiocak, CEO of Voro Therapeutics! Check out his interview: Dr. Ugur Eskiocak is a #cancer #biologist and #biotech entrepreneur with extensive expertise in immuno-oncology, drug development, and translational sciences. He is the CEO & Co-Founder of Voro Therapeutics, where he leads the development of tumor-activated multi-specific antibodies (PrimeBody) to enhance cancer #immunotherapy. Previously, he was an Entrepreneur in Residence at Alloy Therapeutics, Inc., supporting biotech startups and advancing drug discovery. His industry experience includes leadership roles at Janux Therapeutics, Takeda, Xilio Therapeutics, Inc., and Compass Therapeutics Inc., where he directed translational and in vivo #pharmacology programs, contributing to IND-enabling studies and Phase 1 clinical trials. Dr. Eskiocak began his career in academia, conducting postdoctoral research at UT Southwestern Medical Center, where his work on #melanoma metastasis led to a Phase 1b clinical trial. He earned his Ph.D. in Cancer Biology from UT Southwestern and holds a Master’s and Bachelor’s degree in Molecular Biology and Genetics from Orta Doğu Teknik Üniversitesi / Middle East Technical University. Check out www.partnology.com for more biotech leader spotlights! #biotech #biopharma #clinicaldevelopment #drugdevelopment #biotechleaders #biotechexecutives #therapeutics #biotechnology

The Wheeler Bio, Inc. team is excited to announce the close of our latest series of funding to support the expansion of our capabilities here in OKC! With a laser focus on bringing success to our client's programs through our high-science, customer-centered approach, Wheeler is poised and primed to further our mission to change the CDMO landscape in favor of drug innovators and bring more therapies to patients in need. As we grow with our clients and support them throughout their discovery to commercial journey, Wheeler and our partners are more focused than ever on accelerating our client's lifesaving programs. This achievement would not be possible without our lead investors at Alloy Therapeutics, Inc., and Echo as well as our new partners at Mitsubishi Corporation, Russell Westbrook Enterprises, and Germin8 Ventures. Thank you all for your enthusiasm and support. This is only the beginning! #CDMO #Investment #Pharma #Biologics #PR

Congrats to Dren Bio, Inc.! Thrilled to see our partner’s innovation recognized as Sanofi acquires their bispecific myeloid cell engager for deep B-cell depletion.